Renal Insufficiency Clinical Trial
Official title:
Study of Two Modalities of Dialysis and Nutrition on the Nutritional Status of Malnourished Chronic End-stage Renal Disease Patients Dependent on Intradialytic Parenteral Nutrition
Verified date | January 2022 |
Source | GCS Ramsay Santé pour l'Enseignement et la Recherche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Describe the impact of dialysis by high permeability and adsorbent membrane (PEPA®) associated with oral nutritional supplementation on the nutritional status of malnourished chronic end-stage renal disease patients dependent on intradialytic parenteral nutrition.
Status | Completed |
Enrollment | 11 |
Est. completion date | June 4, 2021 |
Est. primary completion date | June 4, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient with renal failure, on hemodialysis for at least 12 months; - Hemodialysis patient in 3 weekly sessions on a device with a standard permeability membrane (polysulfone, polyethersulfone or polyartylethersulfone type); - Malnourished patient, on intradialytic parenteral nutrition for at least 6 months; - Patient who may benefit, according to the doctor, from a change in dialysis and nutrition strategy: - Patient who signed an informed consent form to participate in the study Exclusion Criteria: - Known allergy to PEPA® ; - Protected patient (under legal protection, or deprived of liberty by judicial or administrative decision); - Patient with a chronic infection in progress; - Patient with life expectancy <6 months according to the investigator; - Inability to understand information related to the study (linguistic, psychological, cognitive reason, etc.); - Pregnant woman or likely to be (of childbearing age, without effective contraception) or breastfeeding; - Patient participating in another clinical trial, or in a period of exclusion from another clinical trial; - Patient not benefiting from a social security scheme. |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Privé La Louvière | Lille |
Lead Sponsor | Collaborator |
---|---|
GCS Ramsay Santé pour l'Enseignement et la Recherche |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evolution of the nutritional status | The main endpoint is the evolution between M0 and M6 of the nutritional status measured by the serum albumin level. | Month 6 | |
Secondary | Evolution of nutritional assessment | Evolution of the percentage of weight loss (in Kg) | Month 6 | |
Secondary | Appearance of adverse events | Incidence and characteristics of adverse events / effects | Month 6 | |
Secondary | Measure of the Quality of life | Evolution of the quality of life, evaluated by the EORTC QLQ-C30 questionnaire of the quality of life with 28 questions with 4 possible answers from "not at all" to "a lot of" | Month 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05990660 -
Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery
|
N/A | |
Recruiting |
NCT04096547 -
Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment
|
||
Completed |
NCT04024332 -
Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects
|
Phase 1 | |
Completed |
NCT02849964 -
Factors Related to Geographical Variation in the Incidence of End-stage Renal Failure: An Analysis in 5 French Regions
|
N/A | |
Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
Completed |
NCT01407874 -
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
|
Phase 2 | |
Completed |
NCT01462136 -
PK Study of ACHN-490 Injection in Renally Impaired Subjects
|
Phase 1 | |
Completed |
NCT01172431 -
Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency
|
Phase 4 | |
Completed |
NCT00770081 -
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)
|
Phase 3 | |
Completed |
NCT01545531 -
Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance
|
N/A | |
Completed |
NCT00765830 -
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)
|
Phase 3 | |
Terminated |
NCT00338455 -
Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
|
Phase 2 | |
Completed |
NCT00159614 -
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
|
Phase 2 | |
Completed |
NCT02894385 -
Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)
|
Phase 1 | |
Completed |
NCT02894905 -
A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335
|
Phase 1 | |
Active, not recruiting |
NCT04876963 -
HOLT-ED: Holter-monitoring in End-stage Renal Disease
|
||
Not yet recruiting |
NCT03899298 -
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
|
Phase 1 | |
Completed |
NCT03235375 -
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects
|
Phase 1 | |
Withdrawn |
NCT03329612 -
Remote Ischemic Preconditioning in ACS Patients
|
N/A | |
Recruiting |
NCT02578784 -
DEB-after-Cutting Balloon-PTA in Dialysis Fistula Stenosis
|
N/A |